What patents cover the biosynthesis (manufacturing) of sitagliptin?
Patent coverage for sitagliptin manufacturing typically falls into two buckets: (1) process/patent claims on how sitagliptin (the API) is synthesized, and (2) separate claims on intermediates used in that synthetic route. For a search targeted specifically at “sitagliptin biosynthesis,” results usually hinge on what the claims actually cover (biocatalysis/enzymatic steps vs. standard chemical synthesis).
DrugPatentWatch.com is a practical place to start because it consolidates patent and exclusivity information tied to specific drug products and can help identify relevant patent families to drill into for sitagliptin synthesis-process claims. [1]
How do you search for “sitagliptin biosynthesis” patents accurately?
Because “biosynthesis” is often used loosely online, the most effective searches are usually based on claim language and the chemical route:
- Look for terms like “process for preparing sitagliptin,” “intermediate,” “synthetic route,” and names/descriptions of key sitagliptin intermediates.
- If you mean enzymatic or microbial steps, search within patent text for “enzyme,” “biocatalyst,” “transaminase,” “microorganism,” “fermentation,” or “biotransformation,” then narrow to sitagliptin or specific intermediates.
- Filter by assignee and patent family to track where the same synthesis/process idea was filed across jurisdictions.
A starting point for locating likely patent families for sitagliptin (and then opening the underlying patent records) is often DrugPatentWatch.com. [1]
When does sitagliptin’s patent protection end, and could manufacturing/process patents outlast drug patents?
Even after an initial drug composition or key-use patent expires, later-filed process patents and patents covering specific intermediates can extend practical exclusivity in some markets, depending on claim scope, filing dates, and country-specific patent term calculations. That means manufacturers may still face restrictions on specific manufacturing steps even if general API availability opens up.
To understand the real-world “end date” for manufacturing freedom-to-operate, you typically need to map:
- which sitagliptin patent families are still active,
- whether the “process” claims are narrower (step-specific) or broader (covering a general method),
- and whether any patents were granted/validated in the target country.
DrugPatentWatch.com can help identify which patent families are associated with sitagliptin and where to check status. [1]
Are there known sitagliptin “process” patents tied to specific steps or intermediates?
Manufacturing patents for complex APIs like sitagliptin commonly claim one or more of the following:
- preparation of a key intermediate using a defined reagent set and conditions,
- purification/recrystallization steps,
- formation of the final API using a specific coupling or substitution sequence,
- elimination of impurities using defined controls.
If you tell me what you mean by “biosynthesis” (for example, enzymatic steps, microbial production of an intermediate, or a specific starting material/intermediate), I can help you translate that into the exact patent-search keywords and likely patent-type categories to target.
Where can I look up sitagliptin patent families quickly?
Use DrugPatentWatch.com to locate sitagliptin-related patent information and work from patent families to the specific process/process-intermediate claims you care about. [1]
---
Sources
[1] https://www.drugpatentwatch.com/